What is electroCore?
electroCore, Inc. operates at the intersection of biotechnology and medical device engineering, specializing in non-invasive vagus nerve stimulation (nVNS). The company's proprietary platform is engineered to address a spectrum of neurological conditions, including the preventive and acute treatment of cluster headaches and migraines. By targeting the vagus nerve without the need for surgical intervention, electroCore provides a novel therapeutic alternative for patients suffering from debilitating chronic pain. Its market position is defined by a robust portfolio of indications, extending from adolescent migraine care to complex hemicrania conditions in adults, effectively bridging the gap between traditional pharmaceutical approaches and advanced bioelectronic interventions.
How much funding has electroCore raised?
electroCore has raised a total of $227.4M across 7 funding rounds:
Series A
$50M
Debt
$1.5M
Series B
$70M
Stock Offering
$78M
Share Placement
$25M
Debt
$1M
Stock/Share Issuance
$1.9M
Series A (2014): $50M with participation from Easton Capital, Merck Global Health Innovation Fund, and Core Ventures Group
Debt (2016): $1.5M, investors not publicly disclosed
Series B (2017): $70M supported by The Vinik Family Foundation, American Investment Holdings LLC, Core Ventures Group, Gakasa, and Merck Global Health Innovation Fund
Stock Issuance/Offering (2018): $78M, investors not publicly disclosed
Share Placement (2020): $25M backed by Lincoln Park Capital Fund , LLC
Debt (2020): $1M with participation from PPP
Stock/Share Issuance (2025): $1.9M, investors not publicly disclosed
Key Investors in electroCore
Easton Capital
Easton Capital Investment Group manages approximately $200 million for institutional investors, focusing on early-stage and growth-oriented healthcare and technology ventures.
Merck Global Health Innovation Fund
The corporate venture arm of Merck & Co., Inc., this fund invests in innovative healthcare solutions, including digital health and medical device technologies.
Core Ventures Group
A venture firm founded in 2012 that supports world-class entrepreneurs by investing in seed-stage companies with proven business models and advanced technological capabilities.
What's next for electroCore?
With the successful closure of this major strategic investment, electroCore is poised to enter a new phase of operational expansion. The company is expected to prioritize the commercial scaling of its nVNS platform, focusing on broader market penetration and the potential expansion of its clinical indications. Strategic priorities likely include enhancing patient access, optimizing supply chain efficiencies for its medical devices, and continuing to build a strong evidence base through ongoing clinical research. As the bioelectronic medicine landscape matures, electroCore's ability to integrate its technology into standard clinical workflows will be a key determinant of its long-term market dominance and value creation for stakeholders.
See full electroCore company page
